Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort

References

• Sant M, HAEMACARE Working Group, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17):2902–2913.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–1208.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Berger F, Felman P, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234–5241.
   PubMed Web of Science ®Google Scholar
• Reddy N, Oluwole O, Greer JP, et al. Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2012;12(6):406–411.
   PubMed Web of Science ®Google Scholar
• Guirguis HR, Cheung MC, Piliotis E, et al. Survival of patients with transformed lymphoma in the rituximab era. Ann Hematol. 2014;93:1007–1014.
   PubMed Web of Science ®Google Scholar
• Demirdas S, Hense J, Dührsen U, et al. Treatment outcome in patients with primary or secondary transformed indolent B-cell lymphomas. Oncol Res Treat. 2019;42(11):580–588.
   PubMed Web of Science ®Google Scholar
• Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553–3557.
   PubMed Web of Science ®Google Scholar
• Okosun J, Montoto S, Fitzgibbon J. The routes for transformation of follicular lymphoma. Curr Opin Hematol. 2016;23(4):385–391.
   PubMed Web of Science ®Google Scholar
• Mendez M, Torrente M, Provencio M. Follicular lymphomas and their transformation: Past and current research. Expert Rev Hematol. 2017;10(6):515–524.
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–2433.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5165–5169.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–1594.
   PubMed Web of Science ®Google Scholar
• Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157(2):188–196.
   PubMed Web of Science ®Google Scholar
• Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272–3278.
   PubMed Web of Science ®Google Scholar
• Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013;163(4):487–495.
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126:851–857.
   PubMed Web of Science ®Google Scholar
• Janikova A, Bortlicek Z, Campr V, et al. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Ann Hematol. 2018;97(4):669–678.
   PubMed Web of Science ®Google Scholar
• Alonso-Alvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178(5):699–708.
   PubMed Web of Science ®Google Scholar
• Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981–987.
   PubMed Web of Science ®Google Scholar
• Federico M, Caballero Barrigón MD, Marcheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5:e359–e367.
   PubMed Web of Science ®Google Scholar
• Noy A, Schöder H, Gönen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–512.
   PubMed Web of Science ®Google Scholar
• Novelli S, Briones J, Flotats A, et al. PET/CT assessment of follicular lymphoma and high grade B cell lymphoma – good correlation with clinical and histological features at diagnosis. Adv Clin Exp Med. 2015;24(2):325–330.
   PubMed Web of Science ®Google Scholar
• Madsen C, Clausen MR, Plesner TL, et al. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. Blood Adv. 2018;2(13):1562–1571.
   PubMed Web of Science ®Google Scholar
• Lerch K, Meyer AH, Stroux A, et al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Ann Hematol. 2015;94(6):981–988.
   PubMed Web of Science ®Google Scholar
• Madsen C, Pedersen MB, Vase M, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol. 2015;26:393–399.
   PubMed Web of Science ®Google Scholar
• Ban-Hoefen M, Kelly JL, Bernstein SH, et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2012; 53:830–835.
   PubMed Web of Science ®Google Scholar
• Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health. 2011;39(7 Suppl):72–74.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56.
   PubMedGoogle Scholar
• Arboe B, Josefsson P, Jørgensen J, et al. Danish National Lymphoma Registry. Clin Epidemiol. 2016;8:577–581.
   PubMed Web of Science ®Google Scholar
• Arboe B, El-Galaly TC, Clausen MR, et al. The Danish National Lymphoma Registry: coverage and data quality. PLoS One. 2016;11(6):e0157999.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
   PubMed Web of Science ®Google Scholar
• Binder N, Gerds TA, Andersen PK. Pseudo-observations for competing risks with covariate dependent censoring. Lifetime Data Anal. 2014;20(2):303–315.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737–751.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Longton G, Pettinger M, et al. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol. 1993;83(4):602–607.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A Proportional Hazards Model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28(15):1982–1998.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575–2582.
   PubMed Web of Science ®Google Scholar
• Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761–764.
   PubMed Web of Science ®Google Scholar